

Evaluation of the Xpert *Clostridium difficile* Assay for the Diagnosis of *Clostridium difficile* Infection

Saeam Shin, M.D., Minkyung Kim, M.T., Myungsook Kim, M.T., Heejung Lim, M.T., Heejung Kim, M.D., Kyungwon Lee, M.D., and Yunsop Chong, Ph.D.

Department of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine, Seoul, Korea

Infection with *Clostridium difficile* is a growing concern because of the increasing prevalence and spread of nosocomial infections. Emergence of the hypervirulent 027/NAP1/BI strain is also notable. Existing diagnostic methods have low sensitivity or are time-consuming. Therefore, establishing a rapid and accurate microbiological diagnostic assay is needed. We evaluated the Xpert *C. difficile* assay (Xpert CD assay; Cepheid, USA) to detect toxigenic *C. difficile*. This assay is a real-time multiplex PCR assay that can be used to detect toxigenic *C. difficile* strains and differentiate the *C. difficile* presumptive 027/NAP1/BI strain. A total of 253 loose stool specimens were collected and toxigenic cultures, VIDAS *C. difficile* A & B assays (VIDAS CDAB assay; bioMérieux, France), and the Xpert CD assay were performed. In comparison to toxigenic cultures, the sensitivity, specificity, and positive and negative predictive values were 100%, 94.6%, 83.1%, and 100%, respectively, for the Xpert CD assay and 40.8%, 98.0%, 100%, and 88.9%, respectively, for VIDAS CDAB assay. Because of the low prevalence of the PCR ribotype 027 in Korea, the evaluation of the usefulness of the Xpert CD assay for screening for the 027 strain was limited. The Xpert CD assay provides great sensitivity in diagnosing toxigenic *C. difficile* infection. In addition, this method has excellent usability because it is simple and fast.

Key Words: *Clostridium difficile*, Real-time PCR, Enzyme immunoassay

Received: March 16, 2012

Revision received: April 17, 2012

Accepted: May 25, 2012

Corresponding author: Heejung Kim
Department of Laboratory Medicine,
Yonsei University College of Medicine,
Yongin Severance Hospital, 225 Geumhak-ro,
Cheoin-gu, Yongin 449-930, Korea
Tel.: +82-31-331-8755
Fax: +82-31-335-5551
E-mail: hjkim12@yuhs.ac

© The Korean Society for Laboratory Medicine.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Clostridium difficile is the leading cause of antibiotic-associated diarrhea and pseudomembranous colitis. The increasing prevalence and severity of healthcare-associated *C. difficile* infections (CDI) is of great concern [1]. Moreover, emergence and spread of the hypervirulent 027/NAP1/BI strain of *C. difficile* have been reported in North America and Europe [2-4]. The characteristics of the PCR ribotype 027 strain are production of the *C. difficile* binary toxin (CDT), as well as toxin A/B, and a single nucleotide deletion at position 117 in the *tcdC* gene [4]. The diagnosis of CDI should be based on a combination of symptoms and a positive stool test result for *C. difficile* toxins or toxigenic *C. difficile* [5]. Enzyme immunoassays rapidly detect toxins A and B, but their sensitivity varies greatly among the various products [6]. Toxigenic cultures and cytotoxin assays are considered as gold

standard methods for the detection of toxigenic *C. difficile*, but toxigenic cultures that combine anaerobic cultures and detection of toxin A and B production take at least 48 hr to complete. Cytotoxin assays using cultured cells are also time-consuming and costly, making them unsuitable for routine laboratory diagnosis. Therefore, a rapid and more accurate microbiological diagnostic assay is highly needed for providing optimal patient care and controlling the spread of infections in hospitals.

The Xpert *C. difficile* assay (Xpert CD assay; Cepheid, Sunnyvale, CA, USA) is a real-time multiplex PCR assay performed using the GeneXpert Dx system. The assay uses primers targeted to the cytotoxin gene (*tcdB*), binary toxin genes (*cdtA* and *cdtB*), and a single nucleotide deletion at position 117 in the *tcdC* gene. As a result, the Xpert CD assay can detect toxigenic

C. difficile strains and differentiate *C. difficile* presumptive 027/NAP1/BI. We evaluated the Xpert CD assay for rapidity and accuracy in diagnosing CDI.

A total of 253 consecutive loose stool specimens were collected in a stool specimen container from suspected CDI patients from April to June 2011, in a tertiary hospital. For toxigenic cultures, alcohol-shocked stool specimens were inoculated on *C. difficile* selective agar (CDSA; Becton, Dickinson and Company, Sparks, MD, USA) and incubated at 37°C in an anaerobic chamber (Forma scientific, Marietta, OH, USA) for 48 hr. Suspected *C. difficile* colonies were used to make a gram-stained

smear to observe typical morphology. The species were identified by using the ATB 32A system (bioMérieux, Marcy l'Etoile, France). The identified *C. difficile* isolates were used to detect *tcdA* repetitive regions, *tcdB* as well as *cdtA* and *cdtB* genes, following the previously described PCR method [7] and using the PCR primers listed in Table 1.

Xpert CD assays were performed according to the manufacturer's instructions. A stool specimen was transferred to a vial containing a buffer solution by using a sterile swab. The vial was vortexed, and the solution was then transferred to a cartridge. The test was run on the GeneXpert DX module. The results were reported as *C. difficile*-positive 027/NAP1/BI presumptive negative, *C. difficile*-positive 027/NAP1/BI presumptive positive, *C. difficile*-negative, invalid, error, or no result. The test was repeated if the result was "invalid," "error," or "no result." Sequencing of the *tcdC* gene was performed on isolates that were positive for the presumptive 027/NAP1/BI strain. PCR ribotyping and *tcdC* sequencing were performed in accordance with previously described methods [8, 9] for isolates that tested positive for binary toxin genes in the Xpert CD assay in order to confirm the results.

VIDAS *C. difficile* A & B assays (VIDAS CDAB assay; bioMérieux) were performed according to the manufacturer's instructions. Test results are presented as positive, negative, or equivocal for toxins A and/or B. Specimens with equivocal results were retested once.

By anaerobic culture, 55 of 253 (21.7%) specimens yielded *C. difficile* isolates. Of these, 49 (19.4%) isolates were confirmed to be *tcdB*-positive (Table 2).

Table 1. Sequences of the PCR primers used in this study

Test	Target	Primer	Sequence (5'→3')	Reference
Toxin gene detection	<i>tcdA</i> rep	NK9	CCA CCA GCT GCA GCC ATA	[7]
		NK11	TGA TGC TAA TAA TGA ATC TAA AAT GGT AAC	
	<i>tcdB</i>	NK104	GTG TAG CAA TGA AAG TCC AAG TTT ACG C	
		NK105	CAC TTA GCT CTT TGA TTG CTG CAC CT	
	<i>cdtA</i>	<i>cdtApos</i>	TGA ACC TGG AAA AGG TGA TG	
		<i>cdtArev</i>	AGG ATT ATT TAC TGG ACC ATT TG	
	<i>cdtB</i>	<i>cdtBpos</i>	CTT AAT GCA AGT AAA TAC TGA G	
		<i>cdtBrev</i>	AAC GGA TCT CTT GCT TCA GTC	
Ribotyping	16S-23S	CD1	GCG CCC TTT GTA GCT TGA CC	[8]
	rRNA	CD1445	CTG GGG TGA AGT CGT AAC AAG G	
<i>tcdC</i> sequencing	<i>tcdC</i>	PaL15	TCT CTA CAG CTA TCC CTG GT	[9]
		PaL16	AAA AAT GAG GGT AAC GAA TTT	

Abbreviations: *tcdA* rep, toxin A gene repetitive region; *tcdB*, toxin B gene; *cdtA* and *cdtB*, binary toxin genes.

Table 2. Evaluation of Xpert *Clostridium difficile* and VIDAS *Clostridium difficile* A & B assays for the detection of toxigenic *Clostridium difficile* isolates

Toxigenic culture (N. of isolates)		N. of isolates						
		Xpert CD				VIDAS-CDAB		
		B ⁺ , CDT ⁻ , 027 ⁻	B ⁺ , CDT ⁺ , 027 ⁻	B ⁺ , CDT ⁺ , 027 ⁺	B ⁻ , CDT ⁻ , 027 ⁻	Error	A and/or B Positive	A and/or B Negative
Growth (55)	A ⁺ B ⁺ /A ⁺ B ⁺ , CDT ⁻ (45)	44	1	0	0	0	19	23
	A ⁺ B ⁺ , CDT ⁺ (4)	0	3	1*	0	0	1	2
	A ⁻ B ⁻ , CDT ⁻ (6)	2	0	0	4	0	0	5
No growth (198)		8 [†]	0	0	189	1 [‡]	0	195
Total (253)		54	4	1	193	1	20	225

*One presumptive 027/NAP1/BI strain identified as ribotype 078 on PCR ribotyping as well as a 39-base pair deletion and a point mutation at position 184 in *tcdC*; [†]Four specimens showed positive results by enrichment culture; [‡]One "error" in the Xpert CD assay: no growth on anaerobic culture and negative on VIDAS-CDAB.

Abbreviations: Xpert CD, Cepheid Xpert *Clostridium difficile* assay; VIDAS-CDAB, VIDAS *Clostridium difficile* Toxin A&B assay; A, toxin A; B, toxin B; CDT, *C. difficile* binary toxin; 027, presumptive 027/NAP1/BI strain.

The Xpert CD assay detected *tcdB* in all 49 isolates identified as *tcdB*-positive by toxigenic culture (sensitivity 100%, Table 3). For 8 specimens that tested positive in the Xpert CD assay but were negative upon toxigenic culture, an enrichment culture was performed using cycloserine-cefoxitin fructose broth supplemented with 0.1% sodium taurocholate (TCCFB). Four of these eight specimens yielded a positive result for toxigenic *C. difficile* (Table 4). On the basis of analyses of other samples from the same patients, we suspect that at least 2 samples were contaminated with residual DNA [10]. In 3 undetermined cases, possible explanations for the discrepant results are residual DNA from prior CDI, false-positive PCR result, or true-positive PCR result.

Compared to the toxigenic culture, the sensitivity, specificity, and positive and negative predictive values were 100%, 94.6%, 83.1%, and 100%, respectively, for the Xpert CD assay, and 40.8%, 98.0%, 100%, and 88.9%, respectively, for the VIDAS CDAB assay (Table 3). The overall agreement between the Xpert CD assay and toxigenic culture was 95.7%. Data from the en-

richment culture were not included in the calculation of sensitivity, specificity, and positive and negative predictive values. One “error” case of the Xpert CD assay and 8 “equivocal” cases of the VIDAS CDAB assay were included in the calculation of assay performance (Table 2).

Binary toxin genes (*cdtA* and *cdtB*) were detected in 5 specimens by the Xpert CD assay, and 1 of them showed a 027/NAP1/BI presumptive positive result. The binary toxin genes were confirmed by toxin gene-specific PCR, PCR ribotyping, and *tcdC* sequencing. Four (including one 027/NAP1/BI presumptive positive isolate) of the 5 isolates revealed positive results for binary toxin genes. In addition, all 4 isolates showed an identical pattern to that of ribotype 078 and no deletion at position 117 of the *tcdC* gene. All ribotype 078 strains showed a 39-base pair deletion and a point mutation at position 184 in the *tcdC* gene [11].

Similar to a previous study, the evaluation of the usefulness of the Xpert CD assay for screening for the 027 strain was limited in this study due to the low prevalence of binary toxin-producing

Table 3. Assay performance of Xpert *Clostridium difficile* and VIDAS *Clostridium difficile* A & B assays for the detection of toxigenic *Clostridium difficile* isolates compared with toxigenic culture

Assay	Assay performance (95% confidence interval)*			
	Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)
Xpert CD	100	94.6 (91.5-97.7)	83.1 (73.5-92.7)	100
VIDAS-CDAB	40.8 (27.0-54.6)	98.0 (96.1-99.9)	100	88.9 (84.8-93.0)

*Sensitivity, specificity, PPV, and NPV are calculated as follows ($\times 100$): sensitivity, (number of true-positive assay results)/(sum of toxigenic culture-positive results); specificity, (number of true-negative assay results)/(sum of toxigenic culture-negative results); PPV, (number of true-positive assay results)/(sum of true-positive and false-positive assay results); NPV, (number of true-negative assay results)/(sum of true-negative and false-negative assay results). Abbreviations: Xpert CD, Xpert *Clostridium difficile* assay; VIDAS-CDAB, VIDAS *Clostridium difficile* A & B assay; PPV, positive predictive value; NPV, negative predictive value.

Table 4. Discordant results and further analysis of Xpert *Clostridium difficile* and toxigenic culture*

Sample No.	Enrichment culture	Results		Comment	Possible explanation
		<i>tcdB</i> PCR	VIDAS -CDAB		
1	Growth	Negative	Negative	Previous <i>C. difficile</i> positive (toxigenic culture)	Residual DNA
2	Growth	Negative	Negative	Only one sample submitted	Undetermined [†]
3	Growth	Negative	Equivocal	Only one sample submitted	Undetermined
4	Growth	Positive	Negative	Enrichment culture <i>C. difficile</i> positive (toxigenic culture)	True-positive PCR
5	Growth	Positive	Negative	Enrichment culture <i>C. difficile</i> positive (toxigenic culture)	True-positive PCR
6	Growth	Positive	Negative	Enrichment culture <i>C. difficile</i> positive (toxigenic culture)	True-positive PCR
7	No growth	Not done	Negative	Previous <i>C. difficile</i> positive (toxigenic culture)	Residual DNA
8	No growth	Not done	Negative	Only one sample submitted	Undetermined

*All samples with initially no growth on anaerobic culture and *Clostridium difficile*-positive 027/NAP1/BI presumptive negative on Xpert CD assay; [†]False-positive PCR, residual DNA, or true-positive PCR. Abbreviations: Xpert CD, Cepheid Xpert *Clostridium difficile* assay; VIDAS-CDAB, VIDAS *Clostridium difficile* Toxin A & B assay.

C. difficile strains (3.8% to 7.1%) and PCR ribotype 027 (0.6%) in Korea [12, 13]. A previously published study reported that the agreement between the Xpert CD assay and PCR-ribotyping was 93% [10]. Other studies reported discordant results for the presumptive 027/NAP1/BI strain between the Xpert CD assay and conventional typing and sequencing [14, 15]. These authors reported 1 ribotype 053 strain [15], 1 strain similar to the 078 strain [14], and 6 strains of unknown type. Ribotype 078 is the most frequent type present as a binary toxin-positive strain in Korea [12, 13]. Therefore, results of the presumptive 027/NAP1/BI strain must be interpreted with caution, particularly in Korea, where the prevalence of ribotype 027 is low.

The most significant advantage of the Xpert CD assay is its rapidity and simplicity. A loose stool specimen can be directly used, and the assay takes only 45 min.

In conclusion, the Xpert CD assay is a reliable method for detecting toxigenic *C. difficile* directly from stool specimens and provides greater sensitivity than an enzyme immunoassay.

Authors' Disclosures of Potential Conflicts of Interest

No potential conflicts of interest relevant to this article were reported.

REFERENCES

1. Kelly CP and LaMont JT. *Clostridium difficile*--more difficult than ever. N Engl J Med 2008;359:1932-40.
2. McDonald LC, Killgore GE, Thompson A, Owens RC Jr, Kazakova SV, Sambol SP, et al. An epidemic, toxin gene-variant strain of *Clostridium difficile*. N Engl J Med 2005;353:2433-41.
3. Barbut F, Mastrantonio P, Delmée M, Brazier J, Kuijper E, Poxton I. Prospective study of *Clostridium difficile* infections in Europe with phenotypic and genotypic characterisation of the isolates. Clin Microbiol Infect 2007;13:1048-57.
4. Warrn M, Pepin J, Fang A, Killgore G, Thompson A, Brazier J, et al. Toxin production by an emerging strain of *Clostridium difficile* associated with outbreaks of severe disease in North America and Europe. Lancet 2005;366:1079-84.
5. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, et al. Clinical practice guidelines for *Clostridium difficile* infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hospital Epidemiol 2010;31:431-55.
6. Planche T, Aghaizu A, Holliman R, Riley P, Poloniecki J, Breathnach A, et al. Diagnosis of *Clostridium difficile* infection by toxin detection kits: a systematic review. Lancet Infect Dis 2008;8:777-84.
7. Terhes G, Urbán E, Sóki J, Hamid KA, Nagy E. Community-acquired *Clostridium difficile* diarrhea caused by binary toxin, toxin A, and toxin B gene-positive isolates in Hungary. J Clin Microbiol 2004;42:4316-8.
8. O'Neill GL, Ogunsola FT, Brazier JS, Duerden BI. Modification of a PCR ribotyping method for application as a routine typing scheme for *Clostridium difficile*. Anaerobe 1996;2:205-9.
9. Spigaglia P and Mastrantonio P. Comparative analysis of *Clostridium difficile* clinical isolates belonging to different genetic lineages and time periods. J Med Microbiol 2004;53:1129-36.
10. Babady NE, Stiles J, Ruggiero P, Khosa P, Huang D, Shuptar S, et al. Evaluation of the Cepheid Xpert *Clostridium difficile* Epi assay for diagnosis of *Clostridium difficile* infection and typing of the NAP1 strain at a cancer hospital. J Clin Microbiol 2010;48:4519-24.
11. Goorhuis A, Bakker D, Corver J, Debast SB, Harmanus C, Notermans DW, et al. Emergence of *Clostridium difficile* infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin Infect Dis 2008;47:1162-70.
12. Kim H, Lee Y, Moon HW, Lim CS, Lee K, Chong Y. Emergence of *Clostridium difficile* ribotype 027 in Korea. Korean J Lab Med 2011;31:191-6.
13. Kim H, Jeong SH, Roh KH, Hong SG, Kim JW, Shin MG, et al. Investigation of toxin gene diversity, molecular epidemiology, and antimicrobial resistance of *Clostridium difficile* isolated from 12 hospitals in South Korea. Korean J Lab Med 2010;30:491-7.
14. Huang H, Weintraub A, Fang H, Nord CE. Comparison of a commercial multiplex real-time PCR to the cell cytotoxicity neutralization assay for diagnosis of *Clostridium difficile* infections. J Clin Microbiol 2009;47:3729-31.
15. Tenover FC, Akerlund T, Gerding DN, Goering RV, Boström T, Jonsson AM, et al. Comparison of strain typing results for *Clostridium difficile* isolates from North America. J Clin Microbiol 2011;49:1831-7.